Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests $89
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests $335
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical data sheet

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.
Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  2. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  3. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  4. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  5. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  6. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  7. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  8. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  9. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  10. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  11. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  12. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  13. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  14. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  15. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  16. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  17. Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed
  18. Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed
  19. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  20. Gideon HP, et al. 2022. Immunity. 55:827. PubMed
  21. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  22. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  23. Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed
  24. Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed
  25. Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed
  26. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  27. Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed
  28. Zhu Y, et al. 2022. Immunology. 167:576. PubMed
  29. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  30. Wang Z, et al. 2022. J Exp Med. 219: . PubMed
  31. Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed
  32. Buckner CM, et al. 2022. Cell. 185:4333. PubMed
  33. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  34. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  35. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  36. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  37. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  38. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  39. Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed
  40. Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed
  41. Pleuger C, et al. 2022. Elife. 11: . PubMed
  42. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  43. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  44. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  45. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  46. Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed
  47. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  48. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  49. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  50. Rosain J, et al. 2023. Cell. 186:621. PubMed
  51. Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed
  52. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  53. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  54. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  55. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  56. Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed
  57. Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed
  58. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  59. Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed
  60. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  61. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  62. Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed
  63. Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed
  64. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  65. Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed
  66. Zhao Y, et al. 2022. J Neurosci. . PubMed
  67. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  68. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  69. Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed
  70. Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed
  71. Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed
  72. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  73. Han X, et al. 2022. Nutrients. 14:. PubMed
  74. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  75. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  76. Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed
  77. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  78. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  79. Muri J, et al. 2023. Nat Immunol. 24:604. PubMed
  80. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  81. Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed
  82. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
  83. Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed
  84. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  85. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  86. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  87. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  88. Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed
  89. Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed
  90. Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed
  91. Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed
  92. Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed
  93. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  94. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  95. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  96. Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed
  97. Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed
  98. Imai H, et al. 2023. iScience. 26:106822. PubMed
  99. Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed
  100. Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed
  101. Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed
  102. Wu L, et al. 2023. Cell Res. . PubMed
  103. Cansever D, et al. 2023. Nat Immunol. . PubMed
  104. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  105. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  106. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  107. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  108. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  109. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  110. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  111. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  112. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  113. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  114. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  115. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  116. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  117. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  118. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  119. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  120. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  121. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  122. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  123. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  124. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  125. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  126. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  127. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  128. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  129. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  130. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  131. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  132. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  133. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  134. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  135. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  136. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  137. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  138. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  139. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  140. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  141. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  142. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  143. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  144. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  145. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  146. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  147. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  148. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  149. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  150. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  151. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  152. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  153. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  154. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  155. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  156. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  157. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  158. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  159. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  160. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  161. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  162. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  163. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  164. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  165. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  166. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  167. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  168. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  169. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  170. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  171. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  172. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  173. Woodruff MC, et al. 2022. Nature. :. PubMed
  174. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  175. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  176. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  177. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  178. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  179. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  180. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  181. Akiyama H, et al. 2020. J Virol. . PubMed
  182. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  183. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  184. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  185. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  186. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  187. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  188. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  189. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  190. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  191. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  192. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  193. Mills C, et al. 2022. Cells. 11:. PubMed
  194. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  195. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  196. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  197. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  198. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  199. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  200. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  201. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  202. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  203. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  204. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  205. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  206. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  207. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  208. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  209. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  210. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  211. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  212. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  213. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  214. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  215. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  216. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  217. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  218. Wang Z, et al. 2021. bioRxiv. . PubMed
  219. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  220. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  221. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  222. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  223. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  224. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  225. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  226. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  227. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  228. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  229. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  230. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  231. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  232. Woodruff M, et al. 2020. medRxiv. . PubMed
  233. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  234. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  235. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  236. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  237. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  238. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  239. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  240. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  241. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  242. English KG, et al. 2022. Biomedicines. 10:. PubMed
  243. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  244. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  245. Popay TM, et al. 2021. Elife. 10: . PubMed
  246. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  247. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  248. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  249. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  250. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  251. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  252. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  253. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  254. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  255. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  256. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  257. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  258. Elias G, et al. 2022. Elife. 11:. PubMed
  259. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  260. Ito Y, et al. 2018. Cell. 174:636. PubMed
  261. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  262. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  263. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  264. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  265. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  266. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  267. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  268. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  269. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  270. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  271. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  272. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  273. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  274. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  275. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  276. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  277. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  278. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  279. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  280. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  281. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  282. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  283. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  284. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  285. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  286. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  287. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  288. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  289. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  290. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  291. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  292. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  293. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  294. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  295. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  296. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  297. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  298. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  299. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  300. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  301. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  302. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  303. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  304. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  305. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  306. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  307. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  308. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  309. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  310. Wang Z, et al. 2021. Nature. 592:616. PubMed
  311. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  312. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  313. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  314. Dudek M, et al. 2021. Nature. 592:444. PubMed
  315. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  316. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  317. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  318. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  319. He Y, et al. 2022. Cells. 11:. PubMed
  320. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  321. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  322. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  323. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  324. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  325. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  326. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  327. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  328. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  329. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  330. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  331. Wang Z, et al. 2021. Nature. 595:426. PubMed
  332. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  333. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  334. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  335. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  336. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  337. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  338. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  339. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  340. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  341. Korin B, et al. 2020. Sleep. :43. PubMed
  342. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  343. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  344. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  345. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  346. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  347. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  348. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  349. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  350. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  351. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  352. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  353. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  354. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  355. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  356. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  357. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  358. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  359. Gaebler C, et al. 2020. bioRxiv. . PubMed
  360. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  361. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  362. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  363. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  364. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  365. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  366. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  367. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  368. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  369. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  370. Viant C, et al. 2020. Cell. 183:1298. PubMed
  371. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  372. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  373. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  374. Sibler E, et al. 2021. Cells. 10:. PubMed
  375. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  376. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  377. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  378. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  379. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  380. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  381. Spath S, et al. 2022. iScience. 25:104998. PubMed
  382. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  383. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  384. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  385. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
  386. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  387. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  388. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  389. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  390. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  391. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  392. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  393. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  394. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  395. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  396. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  397. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  398. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed
  399. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  400. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 7    Revision Date: 12/18/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login/Register
Remember me
Forgot your password? Reset Password
Request an Account